News blog

Panel rejects experimental chronic fatigue syndrome drug

A chronic fatigue syndrome drug that spent decades in clinical development and won fervent patient support, has been turned down for approval by a committee of advisers to the US Food and Drug Administration (FDA) who voted 9-4 against it. The drug, named Ampligen (rintatolimod), has not been shown to be effective or safe, the committee determined on 20 December. 

BACK TO ARTICLE

Your details are incomplete or incorrect, please amend the following information

%s

Tell a Friend

Your friend's email address (Required)

Your email (Required)

Message subject (Required)

Message

Verify (Required)

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE